RecruitingNCT04839003
A Registry of AL Amyloidosis (ReAL)
A Registry to Investigate Real-world Natural History, Impact of Therapies and Patterns of Progression of AL Amyloidosis (ReAL)
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Enrollment
5,000 participants
Start Date
Feb 27, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this protocol is to generate a large registry of patients with AL amyloidosis.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria5
- diagnosis of systemic AL amyloidosis;
- treatment-naïve (pre-treatment data collected at participating center available for retrospective part);
- age ≥18 years;
- ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted);
- planned (or ongoing) follow-up at participating center.
Exclusion Criteria2
- non-AL amyloidosis;
- previous treatment for AL amyloidosis.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04839003
Related Trials
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
NCT076386831 location
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
NCT076264761 location
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
NCT06022939117 locations
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
NCT051458163 locations
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
NCT074489351 location